



Fourth Quarter 2018 Results Conference Call
OTCQX: REPR

Forward Looking Statements

This presentation contains forward looking statements that involve risks and uncertainties, including but not limited to those related to our ability to achieve the goals and targets set forth in our Strategic Plan and the addressable market for our products. Actual results and events may differ significantly from results and events discussed in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, the following: introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions. We undertake no obligation to update publicly this presentation or any forward-looking statements to reflect new information, events, or circumstances after the hereof.

Strengthened Management Team

Leadership with 75+ years
of industry experience



Daniel Goldberger
Executive Chairman



Don Pettigrew
President & Chief Executive Officer




Karen Fisher
Chief Financial Officer



Manny Marques
Chief Operating Officer

2018 Highlights



- Refreshed, strengthened management team
- Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets
- Net Revenue increased 12.4% to \$17.4 million from \$15.4 million
- Adjusted EBITDA* expanded to \$2.7 million, up 73.9% from \$1.6 million in 2017

Strategic Plan Through 2022

Goal: to become the preferred drug delivery partner for specific infusion therapies in select markets

\$50M

Revenue*

70%+

Gross Margins*

20%+

Annual organic revenue growth for each year


The Opportunity

\$185-260M

U.S. Addressable PIDD market^{2,3}

\$25-36M

U.S. Addressable CIDP market^{2,3}



Only **20,000** patients are receiving SCIg with the RMS FREEDOM System today³

Only **70,000** patients are receiving Ig therapy today²

1. Immune Deficiency Foundation
2. Industry research
3. RMS estimates

Primary Growth Drivers

PIDD transitioning from IVIg therapy to SubQ Ig therapy

Total addressable market: **70,000** patients today¹

Newly diagnosed PIDD patients expected to be prescribed Ig therapy with SubQ delivery.

Total addressable market: **270,000** patients²

Expanded indications for immunoglobulins delivered with the Freedom system.

Total addressable market for CIDP: **25,000** patients in the U.S. -
Other indications are in the pipeline³

Pharmaceutical companies developing SubQ administration indications for large molecules and biosimilars using the Freedom system. Total addressable market: **1M+ patients¹**

1. Industry research, RMS estimates
2. Immune Deficiency Foundation
3. Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis

Strategic Roadmap

Goal: to become the preferred drug delivery partner for specific infusion therapies in select markets

2019-2020

Phase One

Grow & Harvest

2020-2021

Phase Two

Innovate & Expand

2021 & Beyond

Phase Three

Accelerated Growth

Phase One

**Grow & Harvest
2019-2020**

- Maintain baseline business
- Penetration of PIDD and CIDP
- New product development/launch
- New indications
- Government partnership
- OUS development
- Pharma collaboration
- Funnel of clinical trials
- Margin improvement

Phase Two

**Expand & Innovate
2020-2021**

- Continued execution of Phase 1
- New products
- Expanded indications
- Post acute care
- European expansion

Phase Three

**Accelerated Growth
2021 & Beyond**

- Continued Phase 1 & 2 execution
- New drugs and indications
- Post acute care growth
- Global expansion
- Market share gains

Financial Summary

(\$000's)	Three Months Ended December 31, 2018	Three Months Ended December 31, 2017	Twelve Months Ended December 31, 2018	Twelve Months Ended December 31, 2017
Net Sales	\$4,271	\$4,125	\$17,354	\$15,443
Gross Profit	\$2,714	\$2,490	\$10,810	\$9,268
Gross Margin	63.5%	60.4%	62.3%	60.0%
Net (Loss) Income	(\$355)	\$278	\$911	\$820
Non-GAAP Adjusted EBITDA*	\$448	\$469	\$2,748	\$1,580
Non-GAAP Normalized Net Income**	\$129	\$278	\$1,698	\$820

*Adjusted EBITDA excludes from net income: taxes, depreciation and amortization, interest income, operating expenses associated with the Company's organizational changes and stock compensation expense.

**Normalized net income excludes from net income: operating expenses and tax expense adjustments associated with the Company's organizational changes.

Non-GAAP Reconciliation

(\$000's)	Three Months Ended December 31, 2018	Three Months Ended December 31, 2017	Twelve Months Ended December 31, 2018	Twelve Months Ended December 31, 2017
<i>Reconciliation of GAAP Net (Loss)/Income to Non-GAAP</i>				
GAAP Net Income	(\$355)	\$278	\$911	\$820
Tax (Benefit)/Expense	(\$72)	\$79	\$266	\$391
Depreciation/Amortization	\$80	\$77	\$309	\$307
Interest Income	(\$15)	(\$1)	(\$28)	(\$4)
Reorganization Charges	\$613	-	\$996	-
Stock Compensation Expense	\$196	\$36	\$293	\$67
Non-GAAP Adjusted EBITDA	\$448	\$469	\$2,748	\$1,580
<i>Reconciliation of GAAP Net (Loss)/Income to Non-GAAP Normalized Net income</i>				
GAAP Net (Loss)/Income	(\$355)	\$278	\$911	\$820
Reorganization Charges	\$613	-	\$996	-
Tax (Expense) Adjustment	(\$129)	-	(\$209)	-
Non-GAAP Normalized Net Income	\$129	\$278	\$1,698	\$820

Strategic Plan Through 2022

Goal: to become the preferred drug delivery partner for specific infusion therapies in select markets

\$50M

Revenue*

70%+

Gross Margins*

20%+

Annual organic revenue growth for each year



**Fourth Quarter 2018 Conference Call
OTCQX: REPR**

RMS Medical Products

24 Carpenter Road

Chester, NY 10918

1-800-624-9600

www.rmsmedpro.com

investor@rmsmedicalproducts.com

Investor Relations

Rich Cockrell

CG Capital

1-877-889-1972

www.cg.capital

investorrelations@cg.capital